Valorisation

A revolution in mass electricity storage : ENOGIA will design and deliver the supercritical CO2 turbomachinery of the SCO2OP-TES project

Retrieved on: 
Wednesday, December 20, 2023

Capitalizing on more than a decade of high technology turbomachinery research and development, ENOGIA was selected as the main turbomachinery manufacturing partner of the SCO2OP-TES project.

Key Points: 
  • Capitalizing on more than a decade of high technology turbomachinery research and development, ENOGIA was selected as the main turbomachinery manufacturing partner of the SCO2OP-TES project.
  • ENOGIA will design, engineer, manufacture and test the main supercritical CO2 turbomachines used in this project where a groundbreaking Carnot battery architecture will be developed and tested by the partners of the project.
  • This project emphasizes ENOGIA's recognized ability to develop cutting-edge supercritical CO2 turbomachinery, acquired through years of research and several development projects (including the H2020 I-Therm project).
  • Total funding of the project is 4,7M€, including a grant of 875,5 k€ for ENOGIA to support its activities in the project critical hot sCO2 turbomachinery design, manufacturing and testing.

Global Bio-India 2023 attracts global interest for India's $300 billion biotech potential from companies, academia, and start-ups

Retrieved on: 
Monday, December 4, 2023

Global Bio-India 2023 would be the largest congregation of biotech startups.

Key Points: 
  • Global Bio-India 2023 would be the largest congregation of biotech startups.
  • The central theme of Global Bio-India 2023 is Biotech Innovation and Bio-manufacturing.
  • Global Bio-India 2023 is not just an event; it's an opportunity to shape the future of biotechnology on a global scale  ( Source ).
  • The participation of US biotech leaders in India underscores the strategic importance of the collaboration between two global biotechnology giants.

Green Ammonia Global Market Trends and Opportunities Report 2022: Combining Small-scale Green Ammonia Production with Remote Renewable Generation

Retrieved on: 
Tuesday, August 2, 2022

DUBLIN, Aug. 2, 2022 /PRNewswire/ --The "Green Ammonia: Valorization and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 2, 2022 /PRNewswire/ --The "Green Ammonia: Valorization and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • However, the conventional Haber-Bosch process of ammonia production is an energy-intensive process that releases a high amount of greenhouse gases.
  • Owing to its zero-carbon content, green ammonia can be used to manufacture clean fertilizers and facilitate sustainable farming.
  • Green ammonia can be integrated into existing facilities involved in small-scale renewable generation for the production of urea, ammonium sulfate, ammonium phosphate, and ammonium nitrate.

Green Ammonia Market Report 2022: Fertilizers, Chemicals and Fuels have been Identified as Key Opportunity Areas for Green Ammonia Valorization - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022

However, the conventional Haber-Bosch process of ammonia production is an energy-intensive process that releases a high amount of greenhouse gases.

Key Points: 
  • However, the conventional Haber-Bosch process of ammonia production is an energy-intensive process that releases a high amount of greenhouse gases.
  • Owing to its zero-carbon content, green ammonia can be used to manufacture clean fertilizers and facilitate sustainable farming.
  • What are the new trends in green ammonia production technologies and valorization techniques for the conversion of green ammonia to fertilizers, chemical intermediates, and fuel?
  • Fertilizers, Chemicals, and Fuels have been Identified as Key Opportunity Areas for Green Ammonia Valorization.

Oncode Institute and ArgoBio Launch Laigo Bio, a Targeted Protein Degradation Biotech With Programs in Oncology and Neurological Disorders

Retrieved on: 
Tuesday, February 8, 2022

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.

Key Points: 
  • ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.
  • The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
  • The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications.
  • The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases.

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Retrieved on: 
Wednesday, October 13, 2021

Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.

Key Points: 
  • Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.
  • Professor Bernards commented, We are excited to work with Lixte to identify the most powerful drug combinations of LB-100 for cancer therapy.
  • Our unbiased genetic approach to identify synthetic lethal drug targets of LB-100 has proven its utility in our previous studies.
  • www.lixte.com
    About the Netherlands Cancer Institute, Amsterdam
    The Netherlands Cancer Institute , founded in 1913, is among the worlds best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.